CD6 and CD166/ALCAM SNPs have been identified and validated as risk factors for the development and progression of multiple sclerosis (MS) (40–42), psoriasis severity (43), Behçet's disease risk (44), and inflammatory bowel disease (IBD) risk (45, 46). This evidence concerns the gene CD6 and myeloid sarcoma.